Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing
2012; Wiley; Volume: 91; Issue: 4 Linguagem: Inglês
10.1038/clpt.2011.355
ISSN1532-6535
AutoresMichael A. Martin, Teri E. Klein, Betty J. Dong, Munir Pirmohamed, David W. Haas, Deanna L. Kroetz,
Tópico(s)Pharmaceutical studies and practices
ResumoHuman leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype. Clinical Pharmacology & Therapeutics (2012); 91 4, 734–738. doi:10.1038/clpt.2011.355
Referência(s)